One such derivative, PKC412 (midostaurin), has advanced into phase III clinical trials for the treatment of acute myeloid leukemia (AML) expressing the mutant tyrosine kinase receptor FLT3/CD135, itself a PKC412 target (Fischer et al, 2010). The gene discussed is FLT3; the disease is acute myeloid leukemia.